January - February - March 2014

Lung

 
Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR, Fischer-Valuck BW, Katz SR, Durci M, Wu HT, Syh J, Syh J, Patel B.
Tumori. 2014 Jan-Feb;100(1):42-8. doi: 10.1700/1430.15814.
 
 
A Pulmonary Mass of Unusual Etiology, in a Patient With History of Hodgkin’s Lymphoma.
Aiyappan V, Klebe S, Henderson D, Rose A.
Chest. 2014 Mar 1;145(3 Suppl):321A. doi: 10.1378/chest.1779773.
 
 
Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer.
Castillo R, Pham N, Ansari S, Meshkov D, Castillo S, Li M, Olanrewaju A, Hobbs B, Castillo E, Guerrero T.
Radiat Oncol. 2014 Mar 13;9(1):74. doi: 10.1186/1748-717X-9-74.
 
 
Incidental Mediastinal Dose Does Not Explain Low Mediastinal Node Recurrence Rates in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiotherapy.
Rwigema JC, Chen A, Wang PC, Lee JM, Garon E, Lee P.
Clin Lung Cancer. 2014 Feb 4. pii: S1525-7304(14)00027-8. doi: 10.1016/j.cllc.2014.01.004. 

 
Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer.
Shultz DB, Trakul N, Abelson JA, Murphy JD, Maxim PG, Le QT, Loo BW Jr, Diehn M.
Clin Lung Cancer. 2014 Jan 24. pii: S1525-7304(14)00023-0. doi: 10.1016/j.cllc.2013.12.011. 

 
Assessing the Utility of FDG PET-CT after Stereotactic Body Radiotherapy for Early Stage Non-small Cell Lung Cancer.
Pastis NJ Jr, Greer TJ, Tanner NT, Whalquist AE, Gordon LL, Sharma AK, Koch NC, Silvestri GA.
Chest. 2014 Feb 27. doi: 10.1378/chest.13-2281.
 
 
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, Lerouge D, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Dubray B.
Eur J Nucl Med Mol Imaging. 2014 Feb 22.

 
Indeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of (18)F-FDG PET/CT.
Evangelista L, Panunzio A, Polverosi R, Pomerri F, Rubello D.
AJR Am J Roentgenol. 2014 Mar;202(3):507-14. doi: 10.2214/AJR.13.11728.
 
 
Absence of a relationship between tumor ¹?F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer.
Lin MY, Wu M, Brennan S, Campeau MP, Binns DS, MacManus M, Solomon B, Hicks RJ, Fisher RJ, Ball DL.
J Thorac Oncol. 2014 Mar;9(3):377-82. doi: 10.1097/JTO.0000000000000096.

 
High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size.
Ulger S, Demirci NY, Eroglu FN, Cengiz HH, Tunc M, Tatci E, Yilmaz U, Cetin E, Avci E, Cengiz M.
J Cancer Res Clin Oncol. 2014 Mar;140(3):495-502. doi: 10.1007/s00432-014-1591-9. Epub 2014 Jan 29.
 
 
Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.
Yuan ST, Brown RK, Zhao L, Ten Haken RK, Gross M, Cease KB, Schipper M, Stanton P, Yu J, Kong FM.
Radiat Oncol. 2014 Jan 27;9(1):37.
 
 
Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR.
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):312-8. doi: 10.1016/j.ijrobp.2013.10.029.
 
 
Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Takeda A, Sanuki N, Fujii H, Yokosuka N, Nishimura S, Aoki Y, Oku Y, Ozawa Y, Kunieda E.
J Thorac Oncol. 2014 Jan;9(1):65-73. doi: 10.1097/JTO.0000000000000031.
 
 
Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP.
Ther Adv Respir Dis. 2014 Feb;8(1):3-12. doi: 10.1177/1753465813512545. Epub 2013 Dec 10.
 
 
Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Geiger GA, Kim MB, Xanthopoulos EP, Pryma DA, Grover S, Plastaras JP, Langer CJ, Simone CB 2nd, Rengan R.
Clin Lung Cancer. 2014 Jan;15(1):79-85. doi: 10.1016/j.cllc.2013.08.004. Epub 2013 Oct 8.
 
 
Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L.
Lung Cancer. 2014 Jan;83(1):109-11. doi: 10.1016/j.lungcan.2013.10.006. Epub 2013 Oct 19.
 
 
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y, Onishi H, Nambu A, Araki T.
Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.
 
 
Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy.
Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O’Reilly MS, Erasmus JJ, Fossella FV, Komaki R.
Am J Clin Oncol. 2014 Feb;37(1):77-80. doi: 10.1097/COC.0b013e31826b9cb8.
 
 
 

Head & Neck

 
Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy.
Ito K, Shimoji K, Miyata Y, Kamiya K, Minamimoto R, Kubota K, Okasaki M, Morooka M, Yokoyama J.
Chin J Cancer Res. 2014 Feb;26(1):30-7. doi: 10.3978/j.issn.1000-9604.2014.01.06.
 
 
A prospective clinical study of <sup>18</sup> F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, Grégoire V.
Eur J Nucl Med Mol Imaging. 2014 Feb 26.
 
 
Prognostic value of 18F-fluorodeoxyglucose uptake before treatment for pharyngeal cancer.
Suzuki H, Kato K, Fujimoto Y, Itoh Y, Hiramatsu M, Naganawa S, Hasegawa Y, Nakashima T.
Ann Nucl Med. 2014 Feb 11. 

 
18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA, Troost EG, Bussink J, van Herpen CM, Oyen WJ, Kaanders JH.
Nuklearmedizin. 2014 Jan 28;53(3).
 
 
Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
Grassi I, Nanni C, Cicoria G, Blasi C, Bunkheila F, Lopci E, Colletti PM, Rubello D, Fanti S.
Clin Nucl Med. 2014 Jan;39(1):e59-63. doi: 10.1097/RLU.0b013e3182a756f0.
 
 
Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer.
Picchio M, Kirienko M, Mapelli P, Dell’Oca I, Villa E, Gallivanone F, Gianolli L, Messa C, Castiglioni I.
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):21-31. doi: 10.1007/s00259-013-2528-2. Epub 2013 Aug 29.
 
 
Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS, Iganej S, Thompson LD.
Head Neck. 2014 Jan;36(1):E4-7. doi: 10.1002/hed.23383. Epub 2013 Sep 17.
 
 

Others

 
Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature.
Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM.
Clin Genitourin Cancer. 2014 Feb 28. pii: S1558-7673(14)00039-1. doi: 10.1016/j.clgc.2014.02.006.
 
 
Therapeutic modalities for Pancoast tumors.
Nikolaos P, Vasilios L, Efstratios K, Panagiotis A, Christos P, Nikolaos B, Antonios H, Tsakiridis K, Zarogoulidis P, Zarogoulidis K, Katsikogiannis N, Kougioumtzi I, Machairiotis N, Tsiouda T, Machairiotis N, Madesis A, Vretzakis G, Kolettas A, Dimitrios D.
J Thorac Dis. 2014 Mar;6(Suppl 1):S180-S193. Review.
 
 
IMRT with 18FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer.
Cihoric N, Tapia C, Krüger K, Aebersold DM, Klaeser B, Lössl K.
Radiat Oncol. 2014 Mar 25;9(1):83.
 
 
The predictive role of interim Positron Emission Tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5-point scale interpretation criteria.
Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.
Haematologica. 2014 Mar 21.
 
 
Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial.
Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.
J Clin Oncol. 2014 Mar 17.
 
 
Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, Hessel F, Krause M, Thames H, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B.
Radiother Oncol. 2014 Mar 14. pii: S0167-8140(14)00096-6. doi: 10.1016/j.radonc.2014.02.005. 

 
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN.
Br J Haematol. 2014 Mar 15. doi: 10.1111/bjh.12824.
 
 
A rare association of extragonadal seminoma with synchronous papillary carcinoma of the thyroid.
Barrington C, Bertelli G, Evans R.
BMJ Case Rep. 2014 Mar 13;2014. pii: bcr2013202073. doi: 10.1136/bcr-2013-202073.
 
 
Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force.
Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange JL, Markouizou A, Pfeffer R, Villa S; On behalf of the SIOG Radiotherapy Task Force.
Ann Oncol. 2014 Mar 13. 

 
Role of PET in Lymphoma.
Gallamini A, Borra A.
Curr Treat Options Oncol. 2014 Mar 12. 

 
<sup>11</sup>C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N.
Eur J Nucl Med Mol Imaging. 2014 Mar 6. 

 
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.
Ann Hematol. 2014 Mar 5. 

 
Isolated cerebellar hypermetabolism on FDG PET in a case of remitted primary breast lymphoma.
Reddy AK, Santhosh S, Mittal BR, Bhattacharya A, Sharma SC.
Indian J Nucl Med. 2014 Jan;29(1):55-6. doi: 10.4103/0972-3919.125781.
 
 
Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate.
D’Amico A, Kowalska T.
Indian J Nucl Med. 2014 Jan;29(1):34-7. doi: 10.4103/0972-3919.125769.
 
 
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men.
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA.
Theranostics. 2014 Feb 1;4(4):412-9. doi: 10.7150/thno.7324. eCollection 2014.
 
Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients.
Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO.
J Nucl Med. 2014 Feb 24. 

 
Indeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of (18)F-FDG PET/CT.
Evangelista L, Panunzio A, Polverosi R, Pomerri F, Rubello D.
AJR Am J Roentgenol. 2014 Mar;202(3):507-14. doi: 10.2214/AJR.13.11728.
 
 
Comparison of Tumor Volume Between PET and MRI in Cervical Cancer With Hybrid PET/MR.
Zhang S, Xin J, Guo Q, Ma J, Ma Q, Sun H.
Int J Gynecol Cancer. 2014 Feb 18. 

 
MRI and FDG-PET for Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Aiba T, Uehara K, Nihashi T, Tsuzuki T, Yatsuya H, Yoshioka Y, Kato K, Nagino M.
Ann Surg Oncol. 2014 Feb 15. 

 
FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma.
Choi SH, Chang JS, Jeong YH, Lee Y, Yun M, Seong J.
Liver Int. 2014 Feb 15. doi: 10.1111/liv.12487. 

 
Evaluation of advanced automatic PET segmentation methods using nonspherical thin-wall inserts.
Berthon B, Marshall C, Evans M, Spezi E.
Med Phys. 2014 Feb;41(2):022502. doi: 10.1118/1.4863480.
 
 
An alternative approach to histopathological validation of PET imaging for radiation therapy image-guidance: A proof of concept.
Axente M, He J, Bass CP, Sundaresan G, Zweit J, Williamson JF, Pugachev A.
Radiother Oncol. 2014 Feb;110(2):309-16. doi: 10.1016/j.radonc.2013.12.017. Epub 2014 Jan 30.
 
 
A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ.
Nucl Med Biol. 2014 Feb;41(2):133-9. doi: 10.1016/j.nucmedbio.2013.11.006. Epub 2013 Nov 28.
 
 
Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.
Yuan ST, Brown RK, Zhao L, Ten Haken RK, Gross M, Cease KB, Schipper M, Stanton P, Yu J, Kong FM.
Radiat Oncol. 2014 Jan 27;9(1):37. 

 
Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection.
Yoshii Y, Matsumoto H, Yoshimoto M, Furukawa T, Morokoshi Y, Sogawa C, Zhang MR, Wakizaka H, Yoshii H, Fujibayashi Y, Saga T.
PLoS One. 2014 Jan 22;9(1):e86996. doi: 10.1371/journal.pone.0086996. eCollection 2014.
 
 
Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L, Bergmann R, Brüchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M.
Radiother Oncol. 2014 Feb;110(2):362-9. doi: 10.1016/j.radonc.2013.12.001. Epub 2014 Jan 16.
 
 
What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?
Alongi F, Comito T, Villa E, Lopci E, Cristina I, Mancosu P, Navarria P, Liardo RL, Tomatis S, Chiti A, Scorsetti M.
Acta Oncol. 2014 Jan 17.
 
 
[Differentiation from local tumour recurrence and radionecrosis after stereotactic radiosurgery for treatment of brain metastasis.]
Patsouris A, Augereau P, Tanguy JY, Morel O, Menei P, Rousseau A, Paumier A.
Cancer Radiother. 2014 Jan 13. pii: S1278-3218(13)00444-7. doi: 10.1016/j.canrad.2013.10.013. French.
 
 
Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report.
Johnson SB, Prisciandaro JI, Zhou J, Hadley SW, Reynolds RK, Jolly S.
J Appl Clin Med Phys. 2014 Jan 6;15(1):4520. doi: 10.1120/jacmp.v15i1.4520.
 
 
FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.
Evangelista L, Redana S, Racca M, Geuna E, Vinante L, Zago G, De Carolis V, Ghiotto C, Saladini G, Varetto T.
Clin Nucl Med. 2014 Feb;39(2):e135-41. doi: 10.1097/RLU.0b013e318287353e.
 
 
Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study.
Bartoletti R, Meliani E, Bongini A, Magno C, Cai T.
Oncol Lett. 2014 Feb;7(2):381-386. Epub 2013 Dec 9.
 
 
[Diagnosis and treatment of primary testicular non-Hodgkin lymphoma].
Romics M, Demeter J, Romics I, Nyirády P.
Orv Hetil. 2014 Jan 12;155(2):69-71. doi: 10.1556/OH.2014.29798. Hungarian.
 
 
Visualization, imaging and new preclinical diagnostics in radiation oncology.
Cyran CC, Paprottka PM, Eisenblätter M, Clevert DA, Rist C, Nikolaou K, Lauber K, Wenz F, Hausmann D, Reiser MF, Belka C, Niyazi M.
Radiat Oncol. 2014 Jan 3;9:3. doi: 10.1186/1748-717X-9-3.
 
 
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F.
Chin J Cancer. 2014 Jan;33(1):16-24. doi: 10.5732/cjc.013.10217.
 
 
Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer.
Maffione AM, Chondrogiannis S, Marzola MC, Rampin L, Grassetto G, Ferretti A, Bellan E, Capirci C, Colletti PM, Rubello D.
Clin Nucl Med. 2014 Mar;39(3):e215-9. doi: 10.1097/RLU.0000000000000265.
 
 
Maximum standardized lymph node uptake value could be an important predictor of recurrence and survival in patients with cervical cancer.
Nakamura K, Joja I, Nagasaka T, Haruma T, Hiramatsu Y.
Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:77-82. doi: 10.1016/j.ejogrb.2013.10.030. Epub 2013 Nov 5.
 
 
Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
von Eyben FE, Kairemo K.
Nucl Med Commun. 2014 Mar;35(3):221-30. doi: 10.1097/MNM.0000000000000040.
 
 
Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
Challapalli A, Barwick T, Tomasi G, O’ Doherty M, Contractor K, Stewart S, Al-Nahhas A, Behan K, Coombes C, Aboagye EO, Mangar S.
Nucl Med Commun. 2014 Jan;35(1):20-9. doi: 10.1097/MNM.0000000000000014.
 
 
(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W.
J Nucl Med. 2014 Jan;55(1):30-6. doi: 10.2967/jnumed.113.121418. Epub 2013 Oct 28.
 
 
Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial.
Korst RJ, Bezjak A, Blackmon S, Choi N, Fidias P, Liu G, Marx A, Wright C, Mock S, Rutledge JR, Keshavjee S.
J Thorac Cardiovasc Surg. 2014 Jan;147(1):36-44, 46.e1. doi: 10.1016/j.jtcvs.2013.08.061. Epub 2013 Oct 15.
 
 
First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R.
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):68-78. doi: 10.1007/s00259-013-2540-6. Epub 2013 Oct 9.
 
 
Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer.
Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT.
J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):3-8. doi: 10.1016/j.jmig.2013.07.007. Epub 2013 Jul 31.
 
 
Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.
Marnitz S, Köhler C, Rauer A, Schneider A, Budach V, Tsunoda A, Mangler M.
Strahlenther Onkol. 2014 Jan;190(1):34-40. doi: 10.1007/s00066-013-0403-5. Epub 2013 Jul 27.
 
 
Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS, Iganej S, Thompson LD.
Head Neck. 2014 Jan;36(1):E4-7. doi: 10.1002/hed.23383. Epub 2013 Sep 17.
 
 
Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Karunanithi S, Bandopadhyaya GP, Sharma P, Kumar A, Singla S, Malhotra A, Gupta DK, Bal C.
Clin Nucl Med. 2014 Feb;39(2):e121-8. doi: 10.1097/RLU.0b013e318279bcd8.